Cord blood boost: new technique shows promise for tough leukemia cases

NCT ID NCT04103879

Completed Disease control Sponsor: ExCellThera inc. Source: ClinicalTrials.gov ↗

First seen Apr 02, 2026 · Last updated Jun 17, 2026 · Updated 14 times

Summary

This study tested a new way to prepare cord blood for transplant in 30 people with high-risk leukemia or myelodysplasia. The cord blood was treated with a molecule called UM171 to help it grow more stem cells. The goal was to see if this approach is safe and helps patients recover faster with fewer complications. Early results suggest it may improve survival and reduce side effects like graft-versus-host disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORD BLOOD TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Erasmus Medical Center

Rotterdam, Gelderland, 3015, Netherlands
Fred Hutchinson / University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
University of Colorado School of Medicine. Anschutz Medical Campus

Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.

CORD BLOOD TRANSPLANT HIGH RISK HEMATOLOGICAL MALIGNANCY HIGH RISK HEMATOLOGICAL MALIGNANCY

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

MYELODYSPLASIA